Immune checkpoint inhibitors (ICIs) have revolutionized medical practice in oncology since
the FDA approval of the first ICI 11 years ago. In light of this, Lymphocyte-Activation Gene 3 …

Breast cancer (BC) is known to be a highly heterogeneous disease that is clinically
subdivided into four primary molecular subtypes, each having distinct morphology and …

Lipid-based nanoparticulate delivery platforms such as liposomes help overcome cell and
tissue barriers and allow prolonged therapeutic plasma drug concentrations, simultaneous …

Cancer immunotherapy, a promising and widely applied mode of oncotherapy, makes use of
immune stimulants and modulators to overcome the immune dysregulation present in …

For the treatment of many types of cancers, targeting drug delivery vehicles to the
mitochondria is a major area of interest which provides a significant strategy. This study …

Immunotherapy is gaining prominence as a promising strategy for treating triple-negative
breast cancer (TNBC). Neoantigens (neoAgs) and cancer-testis antigens (CTAs) are tumor …

Lipid-based vaccine delivery systems such as the conventional liposomes, virosomes,
bilosomes, vesosomes, pH-fusogenic liposomes, transferosomes, immuno-liposomes …

Tumor vaccines have been considered a promising therapeutic approach for treating cancer
in recent years. With the development of sequencing technologies, tumor vaccines based on …

T cells suffer from long-term antigen stimulation and insufficient energy supply, leading to a
decline in their effector functions, memory capabilities, and proliferative capacity, ultimately …

Therapeutic strategies for HER2-positive breast cancer with central nervous system involvement:
a literature review and future perspectives - PMC Back to Top Skip to main content NIH NLM …